Finance

Lists
Outlook: 48.4% bullish·4.1% bearish
Go to analysis
LLY:NYSE
Eli Lilly And Co
US$ १,४४३.५०
+१.०४%
(+१४.८०) 1D
US$ १,४५९.०२
+१.०८% (+१५.५२)
Pre-market
Closed: नोभेम्बर १३, १६:०१:०१ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LLY...
Open
US$ १,४२९.९१
High
US$ १,४४९.६४
Low
US$ १,४१९.७७
Mkt. cap
१३.५८ खरब
Avg. vol.
२७.६८ लाख
Volume
३.४३ हजार
Dividend
०.४८%
Quarterly dividend
US$ १.७३
Ex-dividend date
२०२६ नोभेम्बर १३
P/E ratio
४६.८६
52-wk high
US$ १,४६०.००
52-wk low
US$ ८५०.५१
EPS
US$ ३०.८१
Beta
०.४०
Shares outstanding
९४.०७ करोड
No. of employees
५० हजार
Open
US$ १,४२९.९१
High
US$ १,४४९.६४
Low
US$ १,४१९.७७
Mkt. cap
१३.५८ खरब
Avg. vol.
२७.६८ लाख
Volume
३.४३ हजार
Dividend
०.४८%
Quarterly dividend
US$ १.७३
Ex-dividend date
२०२६ नोभेम्बर १३
P/E ratio
४६.८६
52-wk high
US$ १,४६०.००
52-wk low
US$ ८५०.५१
EPS
US$ ३०.८१
Beta
०.४०
Shares outstanding
९४.०७ करोड
No. of employees
५० हजार
News stories
From web sources and news partners
Digital Health News
Digital Health News
·
४० मिनेट पहिले
Eli Lilly’s $1 Bn Hyderabad Investment Gets Fresh Push from Telangana CM
Seeking Alpha
Seeking Alpha
·
१० घण्टा पहिले
Lilly’s Zepbound shows promise in teen obesity trial (LLY:NYSE)
Seeking Alpha
Seeking Alpha
·
१४ घण्टा पहिले
SA Asks: What are the most attractive Big Pharma stocks right now? (LLY:NYSE)
Profile
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
About Eli Lilly And Co
CEODavid A. Ricks
Employees५० हजार
Founded१८७६
Headquartersइन्डियानापोलिस, इन्डियाना, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websitelilly.com
Analyst ratings
Based on 24 analysts giving stock ratings to LLY in the past 3 months
Strong buy
Buy
22
Hold
1
Sell
1
12-month forecast
Based on 24 Wall Street analysts offering 12 month price targets for LLY in the last 3 months.
Highest
Current US$ १,४४३.५०
US$ १,७००.०० (+१७.७७%)
Average
US$ १,५१३.३२ (+४.८४%)
Lowest
US$ ९४०.०० (-३४.८८%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
11/13/2026
Courtney Breen
Bernstein
Buy
Maintained
US$ १,४५०.००
+०.५%
11/13/2026
Evan Seigerman
BMO Capital
Buy
Maintained
US$ १,६५०.००
+१४.३%
11/09/2026
Akash Tewari
Jefferies
Buy
Maintained
US$ १,७००.००
+१७.८%
11/09/2026
Trung Huynh
RBC Capital
Buy
Maintained
US$ १,६००.००
+१०.८%
11/05/2026
David Risinger
Leerink Partners
Buy
Maintained
US$ १,५०८.००
+४.५%
11/02/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
US$ १,६००.००
+१०.८%
11/01/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Maintained
US$ १,६००.००
+१०.८%
10/30/2026
Terence Flynn
Morgan Stanley
Buy
Maintained
US$ १,५९६.००
+१०.६%
10/30/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
US$ १,६१२.००
+११.७%
10/30/2026
Louise Chen
Scotiabank
Buy
Maintained
US$ १,६०५.००
+११.२%
10/30/2026
Asad Haider
Goldman Sachs
Buy
Reiterated
US$ १,५७३.००
+९%
10/30/2026
Jasper Hellweg
Argus Research
Buy
Maintained
US$ १,५५०.००
+७.४%
10/30/2026
Chris Schott
J.P. Morgan
Buy
Reiterated
US$ १,६५०.००
+१४.३%
10/30/2026
Michael Yee
UBS
Buy
Reiterated
US$ १,६२५.००
+१२.६%
10/30/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
US$ १,५००.००
+३.९%
10/29/2026
Geoff Meacham
Citi
Buy
Maintained
US$ १,६५०.००
+१४.३%
10/30/2026
Emily Field
Barclays
Buy
Maintained
US$ १,४००.००
-३%
10/29/2026
Kerry Holford
Berenberg Bank
Buy
Maintained
US$ १,४००.००
-३%
10/20/2026
Steve Scala
TD Cowen
Buy
Maintained
US$ १,२५०.००
-१३.४%
10/01/2026
Umer Raffat
Evercore ISI
Hold
Maintained
-
-
09/23/2026
Jose Luis Pascual
JLPascual
Hold
Maintained
US$ १,०३५.००
-२८.३%
09/23/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
US$ १,२८४.००
-११%
09/17/2026
Luisa Hector
Berenberg Bank
Buy
Upgraded
US$ १,४००.००
-३%
09/14/2026
Rajesh Kumar
HSBC
Sell
Maintained
US$ ९४०.००
-३४.९%
09/10/2026
Nico Chen
DBS
Buy
Maintained
US$ १,५५०.००
+७.४%
08/25/2026
Harry Gillis
Berenberg Bank
Hold
Maintained
US$ १,२२०.००
-१५.५%
08/13/2026
Alexandria Hammond
Wolfe Research
Buy
Maintained
US$ १,३५०.००
-६.५%
05/21/2026
James Shin
Deutsche Bank
Buy
Reiterated
US$ १,२८५.००
-११%
05/07/2026
Last report
२०२६ अक्टोबर २९
Fiscal period
Q3 2026
US$ ७.४८ / US$ ६.३५
+१७.८८%beat
Revenue / Est. (USD)
२४.४० अरब / २२.६२ अरब
+७.८८%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
१९.२९ अरब
१९.८० अरब
२२.९७ अरब
२४.४० अरब
Cost of goods sold
३.३७ अरब
३.५८ अरब
३.२७ अरब
३.९३ अरब
Cost of revenue
३.३७ अरब
३.५८ अरब
३.२७ अरब
३.९३ अरब
Research and development expenses
३.८० अरब
३.५१ अरब
३.८२ अरब
४.२५ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
३.४६ अरब
२.९३ अरब
३.४३ अरब
३.१२ अरब
Operating expense
७.२६ अरब
६.४४ अरब
७.२५ अरब
७.३७ अरब
Total operating expenses
१०.६३ अरब
१०.०२ अरब
१०.५२ अरब
११.३० अरब
Operating income
८.६६ अरब
९.७८ अरब
१२.४६ अरब
१३.०९ अरब
Other non operating income
१८.१२ करोड
१७.०० करोड
५६.१० करोड
३३.९० करोड
EBT including unusual items
८.२७ अरब
८.८५ अरब
९.२५ अरब
८.४१ अरब
EBT excluding unusual items
८.८९ अरब
९.७१ अरब
१२.७३ अरब
१२.८९ अरब
Income tax expense
१.६३ अरब
१.४५ अरब
२.१५ अरब
१.९६ अरब
Effective tax rate
१९.७०%
१६.४३%
२३.२७%
२३.२६%
Other operating expenses
-
-
-
-
Net income
६.६४ अरब
७.४० अरब
७.१० अरब
६.४५ अरब
Net profit margin
३४.४१%
३७.३६%
३०.८८%
२६.४४%
Earnings per share
७.५४
८.५५
८.३८
७.४८
Interest and investment income
६७.२४ करोड
-
-
-
Interest expense
-१५.३३ करोड
-३३.२० करोड
-३४.५० करोड
-३७.८० करोड
Net interest expenses
५१.९१ करोड
-३३.२० करोड
-३४.५० करोड
-३७.८० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
९.२५ अरब
१०.२९ अरब
१२.९९ अरब
१३.६४ अरब
Gain or loss from assets sale
-१८.०० करोड
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू